PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 59 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $4,000 | -55.6% | 2,800 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $9,000 | -10.0% | 2,800 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $10,000 | 0.0% | 2,800 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $10,000 | +11.1% | 2,800 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $9,000 | -10.0% | 2,800 | 0.0% | 0.00% | -20.0% |
| Q3 2020 | $10,000 | -23.1% | 2,800 | 0.0% | 0.01% | -28.6% |
| Q2 2020 | $13,000 | +44.4% | 2,800 | 0.0% | 0.01% | -36.4% |
| Q1 2020 | $9,000 | -25.0% | 2,800 | 0.0% | 0.01% | +37.5% |
| Q3 2019 | $12,000 | -67.6% | 2,800 | 0.0% | 0.01% | -68.0% |
| Q2 2019 | $37,000 | – | 2,800 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |